Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

NEMO syndrome and systemic lupus erythematosus are linked in a new disease association.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

New probes were created to effectively measure specific enzymes involved in fat metabolism, which could help develop new drugs.

Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.

ZNF750 and MPZL3 are important in causing seborrheic dermatitis.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

BMP signaling prevents hair growth by stopping stem cell activation.

Treatments with sunscreen and active ingredients can reduce skin hyperpigmentation by decreasing DNA methylation.

A 73-year-old woman with Hypopigmented Mycosis Fungoides, a rare skin lymphoma, experienced disease progression despite treatment, emphasizing the need for ongoing monitoring.

Nε-(carboxymethyl) lysine delays hair growth by blocking a key protein.

The humanized AA mouse model is better for testing new alopecia areata treatments.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.

Dexamethasone reduces inflammation and delays skin cell changes caused by TPA.

Compound 1 showed promising anticancer activity.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Cystatin M/E strongly inhibits cathepsin V and cathepsin L, important for skin formation.

MMP-9 increase in hair follicles may lead to hair loss.

Certain microRNAs found in normal cells can effectively suppress various cancers.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

The cosmetic product improved melasma and skin quality without causing irritation.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.